Ironwood Places $1B Bet on Biotech That Could Bring Its Next Blockbuster GI Drug

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Ironwood Pharmaceuticals is paying $1 billion to acquire VectivBio, a biotech whose lead program could become a blockbuster treatment for a gastrointestinal disorder. Preliminary Phase 3 data are expected by the end of 2023.

Leave a Replay

Sign up for our Newsletter

Contact Us